Tag: Operation Warp Speed

Posted on

CDC: Healthcare Personnel and Long-term Care Facility Residents should be offered COVID-19 Vaccination First

external content.duckduckgo 6

the staff of the Ridgewood compiled from the CDC website

Ridgewood NJ, In the United States, there is not yet an authorized or approved vaccine to prevent coronavirus disease 2019 (COVID-19). The federal government, through Operation Warp Speedexternal , has been working since the pandemic started to make one or more COVID-19 vaccines available as soon as possible. Although CDC does not have a role in developing COVID-19 vaccines, CDC has been working closely with health departments and partners to develop vaccination plans for when a vaccine is available.

With the possibility of one or more COVID-19 vaccines becoming available before the end of the year, here are things you need to know about where those plans currently stand.

More Information for Healthcare Professionals

Healthcare Professionals

Continue reading CDC: Healthcare Personnel and Long-term Care Facility Residents should be offered COVID-19 Vaccination First

Posted on

Hackensack University Medical Center to Receive COVID Vaccine

95730664 10220484969849746 1802800672681230336 n

the staff of the Ridgewood blog

Hackensack NJ, the first COVID vaccines are expected to arrive in New Jersey within a matter of days . Six hospitals have been selected to receive the super-cold cases of frozen vaccine as part of a dry run by Operation Warp Speed.

Continue reading Hackensack University Medical Center to Receive COVID Vaccine

Posted on

Americans to Receive Vaccine for Free in Trump Administration COVID Deal with Pfizer

Pfizer Logo

the staff of the Ridgewood blog

The US government has finalized an agreement with Pfizer and BioNTech to acquire 100 million doses of their candidate SARS-CoV-2 vaccines, worth US$1.95 billion. Additionally, the US government could purchase an additional 500 million doses under the agreement. Pfizer and BioNTech currently have several candidate vaccines in the development pipeline, including various stages of clinical trials. According to a press release issued by Pfizer, the companies aim to begin Phase 2b/3 clinical trials later this month with the goal of securing US FDA authorization for at least one vaccine by October and delivering the vaccine doses by the end of 2020. The companies also hope to expand production to a total of 1.3 billion doses by the end of 2021. The agreement was signed as part of Operation Warp Speed, which has resulted in similar agreements—to support research and development, scale up manufacturing capacity, and purchase vaccine doses—with other pharmaceutical companies pursuing their own candidate vaccines.

Continue reading Americans to Receive Vaccine for Free in Trump Administration COVID Deal with Pfizer

Posted on

Moderna, Inc., issues encouraging preliminary results from its Phase 1 COVID19 vaccine trial

Moderna2

the staff of the Ridgewood blog

Washington DC, Last week, US President Donald Trump provided additional details on Operation Warp Speed, the US plan to rapidly develop, test, and manufacture a SARS-CoV-2 vaccine. The program will involve senior experts and leadership from both the US Department of Health and Human Services and the Department of Defense, and it aims to develop, test, and scale up production for a SARS-CoV-2 vaccine in order to make millions of doses available by early 2021. This would be a monumental effort and would considerably accelerate the process for any previous vaccine by months or years. One of the project leaders, Dr. Moncef Slaoui, commented that he had recently seen encouraging preliminary data from early clinical trials of a vaccine candidate. This morning, Moderna, Inc., issued a press release describing encouraging preliminary results from its Phase 1 vaccine trial. While Phase 1 trials are designed to evaluate safety of the vaccine in humans, Moderna noted that early data (based on only 8 participants) are promising that the vaccine could induce the development of protective antibodies. More data is required to better characterize the body’s immune response, particularly with respect to the effect on conferring immunity to SARS-CoV-2.